Literature DB >> 6952920

Proposals for the classification of the myelodysplastic syndromes.

J M Bennett, D Catovsky, M T Daniel, G Flandrin, D A Galton, H R Gralnick, C Sultan.   

Abstract

New diagnostic criteria for the diagnosis of the various myelodysplastic syndromes (MDS) are proposed, and a detailed description is given of the features that may help define MDS. Five MDS are described: (1) refractory anaemia (RA), (2) RA with ring sideroblasts, (3) RA with excess of blasts (RAEB), (4) chronic myelomonocytic leukaemia (CMML), and (5) RAEB 'in transformation'. One of the main distinguishing features of these conditions is the proportion of blast cells in the peripheral blood (PB) and/or bone marrow (BM). The morphological features of the blast cells that are of diagnostic importance have been redefined. In RA, with or without ringed sideroblasts, there are fewer than 1% of blasts in the PB and fewer than 5% in the BM; RAEB is defined as having between 5% and 20% of blasts in the BM and fewer than 5% in the PB; RAEB in transformation (a newly defined category) will be considered when any of the following features is present: (i) more than 5% of blasts in the PB, (ii) 20-30% in the BM, and (iii) the presence of Auer rods in granulocyte precursors in BM or PB. In accordance with these newly defined criteria, it is now proposed that over 30% of bone marrow blasts will suffice for the diagnosis of acute myeloid leukaemia (AML) in any of its forms (M1-M6). The proposed descriptions of the MDS should facilitate the interpretation of data emerging from cytogenetic and bone marrow culture studies and the search for features of possible prognostic significance. Recognition of the new category, RAEB in transformation, may throw light on the pathogenesis of AML.

Entities:  

Mesh:

Year:  1982        PMID: 6952920

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  484 in total

Review 1.  A strategy for erythropoietin treatment in myelodysplastic syndromes.

Authors:  R Hast
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

2.  Pyrexia of unknown origin, the age-old dilemma.

Authors:  P Deshpande; T Brammah; H Rakicka
Journal:  Postgrad Med J       Date:  1998-12       Impact factor: 2.401

3.  Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.

Authors:  Julie Schanz; Christian Steidl; Christa Fonatsch; Michael Pfeilstöcker; Thomas Nösslinger; Heinz Tuechler; Peter Valent; Barbara Hildebrandt; Aristoteles Giagounidis; Carlo Aul; Michael Lübbert; Reinhard Stauder; Otto Krieger; Guillermo Garcia-Manero; Hagop Kantarjian; Ulrich Germing; Detlef Haase; Elihu Estey
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

4.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

5.  Possibility of the diagnosis of subacute myeloid leukemia for a group of patients with trisomy 8: a report of 34 cases.

Authors:  Yan Zhang; Jing-Ying Qiu; Yue-Yun Lai; Dao-Pei Lu
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

6.  Simultaneous demonstration of clonal chromosome abnormalities and apoptosis in individual marrow cells in myelodysplastic syndrome.

Authors:  Xiao Li; C Eileen Bryant; H Joachim Deeg
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

7.  Myelofibrosis in primary myelodysplastic syndromes: clinical and biological significance.

Authors:  D Marisavljević; Z Rolović; V Cemerikić; D Bosković; M Colović
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

8.  Reticulocyte maturity as an indicator for estimating qualitative abnormality of erythropoiesis.

Authors:  K Watanabe; Y Kawai; K Takeuchi; N Shimizu; H Iri; Y Ikeda; B Houwen
Journal:  J Clin Pathol       Date:  1994-08       Impact factor: 3.411

9.  Apoptotic rate in patients with myelodisplastic syndrome treated with modulatory compounds of pro-apoptotic cytokines.

Authors:  Elena Moldoveanu; Andreea Moicean; Cristina Vidulescu; Daciana Marta; Adriana Colita
Journal:  J Cell Mol Med       Date:  2003 Jul-Sep       Impact factor: 5.310

10.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.

Authors:  H Nagata; A S Worobec; C K Oh; B A Chowdhury; S Tannenbaum; Y Suzuki; D D Metcalfe
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.